Scientists race to find better treatments for Tough-to-Treat blood cancer

NCT ID NCT02436707

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

Summary

This study is testing new combinations of cancer drugs to see if they work better than the current standard treatment for aggressive B-cell lymphoma that has come back or stopped responding to initial therapy. About 129 patients will be randomly assigned to receive either a new drug combination or the standard regimen. The main goal is to see how many patients' cancer shrinks or disappears with the new treatments, while closely monitoring side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, T2N 5G2, Canada
BCCA - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)

Québec, Quebec, G1J 1Z4, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
QEII Health Sciences Centre

Halifax, Nova Scotia, B3H 1V7, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.

LYMPHOMA